Neptune Technologies & Bioresources (Nasdaq: NEPT ) reported earnings on Oct. 15. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Aug. 31 (Q2), Neptune Technologies & Bioresources beat expectations on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly and GAAP loss per share grew.
Margins contracted across the board.
Neptune Technologies & Bioresources logged revenue of $8.2 million. The one analyst polled by S&P Capital IQ predicted revenue of $7.7 million on the same basis. GAAP reported sales were 84% higher than the prior-year quarter's $4.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.08. The one earnings estimate compiled by S&P Capital IQ forecast $0.01 per share. GAAP EPS were -$0.08 for Q2 compared to -$0.02 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 37.7%, 1,340 basis points worse than the prior-year quarter. Operating margin was -49.4%, 300 basis points worse than the prior-year quarter. Net margin was -48.1%, 2,340 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $8.4 million. On the bottom line, the average EPS estimate is $0.01.
Next year's average estimate for revenue is $29.9 million. The average EPS estimate is $0.02.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 29 members out of 174 rating the stock outperform, and 145 members rating it underperform. Among 97 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), three give Neptune Technologies & Bioresources a green thumbs-up, and 94 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Neptune Technologies & Bioresources is outperform, with an average price target of $8.28.